ribosomal protein L18a pseudogene 2Genealiases: []
Q-omics provides the consensus-scored RPL18AP2 profile across patient tissues and cancer cell-line models. RPL18AP2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPL18AP2 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, RPL18AP2 RNA expression shows 12,103 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, BRCA, and TGCT as cancer lineages where RPL18AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL18AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL18AP2 survival associations across molecular data types. RPL18AP2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL18AP2 RNA expression–survival associations across cancer types. High RPL18AP2 expression shows unfavorable associations in STAD, COAD and BLCA, but favorable associations in SKCM, PAAD and UCS. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPL18AP2 RNA expression.
This table summarizes RPL18AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL18AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL18AP2 shows higher tumor expression in BRCA, LUSC, STAD, LIHC, UCEC and LUAD. The BRCA box plot shows higher RPL18AP2 RNA expression in tumor versus normal tissue (log2 FC = +0.208, t-test p = .002).
This table shows molecular features associated with RPL18AP2 in patient tissues and cancer cell lines. In patient samples, RPL18AP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
